诊疗一体化应用进展:探索成纤维细胞激活蛋白抑制示踪剂在提升甲状腺健康评估中的作用
本文为叙述性综述,总结FAPI PET显像在甲状腺癌及成纤维细胞激活蛋白靶向放射性核素治疗中的现有文献,概述FAPI在正常甲状腺组织、甲状腺癌及其转移灶中的摄取,比较FAPI与[18F]-FDG在甲状腺病变中的摄取差异,并讨论FAPI在碘难治性甲状腺癌中的治疗价值。结论认为FAPI在甲状腺癌中具有重要前景,可为临床医生未来更精准的诊断选择和治疗策略提供有价值的信息。
要点
- FAPI在肿瘤中高表达而正常组织 largely 不表达,是甲状腺癌诊断的 promising 工具。
- 综述概述FAPI在正常甲状腺组织、甲状腺癌及其转移灶中的摄取特征。
- 综述比较FAPI与[18F]-FDG在甲状腺病变中的摄取差异。
核心结论
- 成纤维细胞激活蛋白抑制剂在甲状腺癌中的应用具有重要前景,可为临床医生未来更精准的诊断选择和治疗策略提供有价值的信息。
研究设计与样本
- 本文为叙述性综述,总结FAPI PET显像用于甲状腺癌及成纤维细胞激活蛋白靶向放射性核素治疗的现有文献。
主要发现
- [18F]-FDG PET显像准确识别甲状腺病变的诊断准确性有限,主要由于正常头颈部组织的生理性摄取和淋巴结的炎性摄取。
- 成纤维细胞激活蛋白在肿瘤中高表达而在正常组织中 largely 不表达。
- 综述概述了FAPI在正常甲状腺组织、甲状腺癌及其转移灶中的摄取。
- 综述重点比较了FAPI摄取与[18F]-FDG摄取在甲状腺病变中的差异。
- 综述讨论了FAPI在碘难治性甲状腺癌中的治疗价值。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The diagnostic accuracy of [18F]-fluorodeoxyglucose ([18F]-FDG) positron emission tomography imaging in accurately identifying thyroid lesions is limited, primarily due to the physiological uptake of normal head and neck tissues and inflammatory uptake in lymph nodes. Since fibroblast activating protein is highly expressed in tumors and largely unexpressed in normal tissues, quinoline-based fibroblast activating protein inhibitors (FAPI) have emerged as promising tools in the diagnosis of cancer and other medical conditions. Several studies have reported on the feasibility and value of FAPI in thyroid cancer. MAIN BODY: In this narrative review, we summarize the current literature on state-of-the-art FAPI positron emission tomography imaging for thyroid cancer and fibroblast activating protein-targeted radionuclide therapy. We provide an overview of FAPI uptake in normal thyroid tissue, thyroid cancer and its metastases. Additionally, we highlight the difference between FAPI uptake and [18F]-FDG uptake in thyroid lesions. Furthermore, we discuss the therapeutic value of FAPI in iodine-refractory thyroid cancer. CONCLUSION: The utilization of fibroblast activating protein inhibitors in thyroid cancer holds significant promise, offering clinicians valuable insights for more precise diagnose choices and treatments strategies in the future.
引用
- Wang Y, Liu Y, Geng H, et al. Advancements in theranostic applications: exploring the role of fibroblast activation protein inhibition tracers in enhancing thyroid health assessment. EJNMMI Res. 2023. PMID: 38129604. doi:10.1186/s13550-023-01060-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。